Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. HIV Med. 13:309-14.. 2012.
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.. 2012.
The prevalence of darunavir-associated mutations in HIV-1-infected children in the UK. Antivir Ther. 17:599-603.. 2012.
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score PLoS One. 6:e25665.. 2011.
Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. J Antimicrob Chemother. 66:1886-96.. 2011.
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 11:363-71.. 2011.
Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.. 2011.
The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.. 2011.
Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.. 2011.
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia. J Infect Dis. 201:1303-7.. 2010.
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS. 24:1917-22.. 2010.
Epidemiology of non-B clade forms of HIV-1 in men who have sex with men in the UK. AIDS. 24:2397-401.. 2010.
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.. 2010.
The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.. 2010.
The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.. 2010.
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.. 2010.
Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clin Infect Dis. 50:1275-85.. 2010.